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1. Introduction
Selective internal radiation therapy (SIRT) with yttrium-
90 microspheres is a promising treatment modality in
patients with either primary or metastatic liver tumours.
It is usually recommended for patients with advanced
disease who are not candidates for local ablation, surgical
resection, liver transplantation (LT) or for patients who
have failed other treatments. 1
2. Patient population
Since April 2007, 177 patients with unresectable and
untransplantable HCC have been considered for SIRT at
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the General Surgery and Transplantation Center of the
National Institute of Infectious Disease “L. Spallanzani”.
Treatment was conducted in cooperation with the Inter-
ventional Radiology and Nuclear Medicine Unit of the
National Cancer Institute “Regina Elena”. Eligibility for
SIRT was reviewed by a multidisciplinary panel. Pre-LT
screening included: a review of the patient’s clinical his-
tory (age, risk factors, comorbidities), diagnostic imaging
by MRI and CT, determination of the level of underlying
liver disease according to Child–Pugh and Model for End
Stage Liver Disease (MELD) and disease stage according
to UNOS Tumor-Node-Metastases (TNM) and Barcelona
Clinic Liver Cancer (BCLC) classiﬁcations. The Eastern
Cooperative Oncology Group (ECOG) performance status
was also assessed for each patient.
Patients were considered eligible for SIRT if they
presented with: preserved liver function with normal
bilirubin, INR< 1.2 and absence of ascites and with ECOG
performance status ‘0’ or ‘1’. SIRT is performed using
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Table 1 – Baseline patient characteristics and HCC features in 7 transplant recipients
Pt no. Age HCC location Vascular
thrombosis
Milan
criteria
Interval SIRT-LT (mo)
1 63 − OUT 12
2 64 YES OUT 30
3 40 YES OUT 14
4 50 − IN 2
5 59 − IN 8
6 48 − OUT 9
7 48 − OUT 13
Table 2 – Radiological and pathological features before and after SIRT in 7 transplant recipients
Pt no. Radiological Milan
Before Y-90 After Y-90
Pathological Milan Microvascular invasion
1 5 nodules IN 4 nodules (0.5, 0.7, 1.0, 1.7 cm) NO
2 2 nodules (8 cm, 1 cm) IN 2 nodules (0.5, 0.5 cm) NO
3 1 nodule (3 cm) IN No HCC NO
4 1 nodule (3 cm) IN 1 nodule (1.7 cm) NO
5 2 nodules IN 5 nodules (1.0, 1.5, 2.0, 2.5, 3.5 cm) NO
6 5 nodules IN 5 nodules (0.5−1.2 cm) NO
7 4 nodules IN 3 nodules (0.5, 0.5, 1.8 cm) NO
90Y resin microspheres (SIR-Spheres, Sirtex Medical,
Sydney, Australia). All patients had pretreatment mesen-
teric angiography and 99Tc-macroaggregated albumin
scanning for the assessment of non-target distribution
of the 90Y microspheres and the embolisation of aberrant
vessels. All patients were followed-up for toxicities
and adverse events. During follow-up all patients were
monitored by CT scans at 1 month and subsequently at
3-month intervals.
Overall 36 of 177 patients with intermediate–advanced
stage (BCLC B and C), who received SIRT were considered
possible candidates for LT. Patients were selected for LT
based on: age <65 years, downstaging to within Milan
criteria for number and size of nodules, and an absence
of extra-hepatic spread or gross vascular invasion. 2
Among the 36 patients considered for LT after SIRT,
19 were excluded from the LT programme due to drug
or alcohol abuse, HIV infection beyond the LT criteria or
disease progression. Of the remaining 17 patients, SIRT
had been used to downstage 13 patients and as a bridging
treatment for LT in 4 patients. Ten patients were treated
with SIRT before being put on the LT waiting list and
7 patients received SIRT while on the waiting list because
of tumor progression.
3. Transplantation
Seven patients had a liver transplantation post-SIRT.
Six patients had cadaveric donor liver transplantation
and 1 patient received living donor liver transplantation.
Analyses of the baseline characteristics of these patients
prior to SIRT (Table 1) show that two patients had had
neoplastic inﬁltration of a portal vein branch which
disappeared after SIRT. Evaluation of the explanted livers
found that one patient did not meet the Milan criteria
(patient 5; Table 2). Side effects after SIRT included:
fatigue, ALT increase and worsening of hepatic function,
and one case of hepatic decompensation and the
development of ascites. All patients were transplanted
with the so-called “piggy back” technique without any
complications to the vascular anastomosis. SIRT induced
signiﬁcant atrophy of the liver targeted area with
compensatory hypertrophy of the untreated liver and
appeared to increase the difﬁculty of the inferior vena
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Table 3 – Treatment follow up of the
7 transplant recipients
Pt no. Age MELD Follow up
LT SIRT
Status
1 63 12 36 48 Alive
2 64 10 27 55 Alive
3 40 10 17 30 Alive
4 50 11 16 18 Alive
5 59 8 4 12 Alive
6 48 10 3 12 Alive
7 48 13 11 24 Alive
cava dissection during LT. All patients were alive at
follow-up as shown in Table 3.
4. Conclusions
In summary, SIRT using intra-arterial 90Y-labelled micro-
spheres has proved to be one of the most effective
locoregional techniques for treating advanced HCC at
our centre. As outlined above, a certain proportion
of patients initially excluded from the transplant list
were downstaged following SIRT and became potential
candidates for LT.
Our experience with LT after SIRT is limited to
7 cases, but shows that SIRT can be utilised in the liver
transplant setting as a bridge to transplant, controlling
tumour progression for those on the waiting list.
Alternatively, SIRT can be used to downstage tumours
and/or achieve resolution of vascular invasion, thereby
enabling access to the organ waiting list for those outside
the conventional criteria.
In conclusion, SIRT represents an important evolution
of our downstaging and bridging techniques and
currently plays an integral role in the management of
our patients with HCC before transplantation. 3,4 This
procedure may ultimately lead to an evolution in our
selection of transplant candidates and the allocation of
livers; although additional long-term follow-up data are
needed.
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